Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
14.4M
-
Shares change
-
+900K
-
Total reported value, excl. options
-
$393M
-
Value change
-
+$29.3M
-
Put/Call ratio
-
2.4
-
Number of buys
-
47
-
Number of sells
-
-41
-
Price
-
$27.26
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q3 2016
119 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q3 2016.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.4M shares
of 27.8M outstanding shares and own 51.88% of the company stock.
Largest 10 shareholders include Birchview Capital, LP (2.18M shares), VANGUARD GROUP INC (1.05M shares), CANNELL PETER B & CO INC (1.05M shares), FIRST REPUBLIC INVESTMENT MANAGEMENT, INC. (741K shares), Nuveen Asset Management, LLC (701K shares), Arrowpoint Asset Management, LLC (683K shares), BlackRock Institutional Trust Company, N.A. (646K shares), Newtyn Management, LLC (600K shares), BlackRock Fund Advisors (591K shares), and LOOMIS SAYLES & CO L P (570K shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.